(Reuters) - Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the ...

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine ...

Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate sufficient efficacy in preventing invasive E. coli disease No safety signals related to ...

MINNEAPOLIS — A Minnesota company has won federal approval to become the first in the U.S. to market an E. coli vaccine for cattle, a new weapon against a foodborne disease that can cause serious ...

Sanofi and J&J discontinued E.mbrace phase 3 study after the vaccine showed insufficient efficacy in preventing invasive E. coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 2024 ...

Vaccines targeting common gut bacteria E.coli could reduce rates of colon cancer in countries such as the UK, scientists have suggested. Professor Jukka Corander, senior author from the Wellcome ...

Last month, an E. coli outbreak swept through McDonald’s restaurants in 13 states, killing one person and sickening 89 others, including 27 people who needed to be hospitalized. Within days, an ...

LONDON, May 3 (Reuters) - Scientists at drugmaker Novartis have found bacterial components they hope can be used to develop a vaccine to protect people against a range of dangerous Escherichia coli (E ...